Patient guide · Reviewed June 2026
Online vs In-Person GLP-1 Prescription in Australia — What's the Difference?
Both online (telehealth) and in-person GLP-1 prescriptions are clinically valid in Australia. Both involve AHPRA-registered doctors. Both can prescribe the same medications. But they differ significantly in what happens after the prescription — and that difference has real clinical consequences for the 500,000 Australians currently on GLP-1 medications.
Published 2026-06-01 · Clinically reviewed 2026-06-03
Patient guide · Reviewed June 2026
What Telehealth GLP-1 Services Provide
Australian telehealth GLP-1 platforms — Juniper, Moshy, Pilot, and others — have made GLP-1 medications accessible to patients who previously had no pathway.…
Australian telehealth GLP-1 platforms — Juniper, Moshy, Pilot, and others — have made GLP-1 medications accessible to patients who previously had no pathway. This is genuinely valuable. The typical telehealth pathway provides:
- Initial eligibility assessment (BMI, comorbidities, contraindications)
- Video or phone consultation with an AHPRA-registered doctor
- Private prescription issued if eligible
- Dose escalation guidance and schedule
- Side effect management support via messaging
- Monthly prescription renewal
- Optional add-on blood tests in some programmes
The research on telehealth GLP-1 outcomes: In one study, telehealth patients on semaglutide achieved weight loss comparable to clinical trial benchmarks. This is reassuring for the effectiveness of the prescribing model itself.
The identified gap: A 2026 study published in the Journal of Medical Internet Research examined the clinical support gap in telehealth-based GLP-1 care. The analysis found that one of the biggest potential drawbacks is the lack of ongoing clinical support for patients. A 2026 Obesity Reviews scoping review examined 12 clinical trials on patients taking GLP-1 medications and found that only three of the 12 studies involved a registered dietitian, and patients frequently had inadequate protein intake alongside significant lean tissue loss — with 40% of weight lost being lean tissue rather than fat in some studies.
What In-Person GP Care Provides
An in-person GP managing a GLP-1 patient delivers the full monitoring pathway recommended by Australian guidelines:
Baseline assessment:
- Full metabolic blood panel including liver function, kidney function, thyroid
- FIB-4 calculation for fatty liver risk assessment
- Blood pressure, weight, waist circumference, body composition
- Cardiovascular risk assessment
- Dietitian referral via Chronic Disease Management Plan (Medicare subsidised)
Ongoing monitoring:
- 3-month review with repeat blood panel during dose escalation
- Annual review with full metabolic panel and FIB-4 recalculation
- Liver elastography referral if FIB-4 is indeterminate
- Management of any developing complications
Referral pathway:
- Hepatologist if liver disease is identified
- Endocrinologist for complex metabolic management
- Cardiologist for cardiovascular risk patients
- Psychologist if eating disorder history or body image concerns
Clinical relationship: An in-person GP builds a longitudinal clinical relationship. They know your history, track your progress across years, and can identify emerging issues before they become complications.
Patient guide · Reviewed June 2026
The Key Clinical Differences
| Care element | Telehealth GLP-1 service | In-person GP |
|---|---|---|
| Prescription | ✓ | ✓ |
| Dose management | ✓ | ✓ |
| Baseline blood tests | Optional add-on in some | ✓ Standard |
| FIB-4 calculation | Rarely | ✓ If GP informed |
| Liver elastography referral | ✗ | ✓ If FIB-4 indeterminate |
| Dietitian referral (CDM Plan) | ✗ | ✓ |
| Kidney function monitoring | Rarely | ✓ |
| Thyroid monitoring | Rarely | ✓ |
| 3-month review | Messaging/video | ✓ Clinical appointment |
| Cardiovascular risk review | ✗ | ✓ |
| Referral to specialist | ✗ | ✓ |
The Monitoring Gap This Creates
The MJA September 2025 consensus statement is explicit: all adults with type 2 diabetes, obesity, or metabolic risk factors — which includes every GLP-1 patient — should have their liver assessed using the FIB-4 to elastography pathway.
Most telehealth GLP-1 patients have never had this assessment. They received a prescription but no FIB-4. No liver function tests. No baseline for comparison when something changes.
This is not a criticism of the telehealth platforms per se — streamlined prescribing at scale does not easily incorporate comprehensive metabolic monitoring. It is a structural gap in how GLP-1 care is currently delivered in Australia.
Patient guide · Reviewed June 2026
The Right Approach for Most Patients
For convenience and initial access: Telehealth platforms provide the most accessible pathway to GLP-1 medications in Australia, particularly for patients in…
For convenience and initial access: Telehealth platforms provide the most accessible pathway to GLP-1 medications in Australia, particularly for patients in regional areas or without easy GP access. If your GP has long waiting times or is unfamiliar with GLP-1 prescribing, a telehealth consultation for the prescription is a legitimate pathway.
For ongoing management: An in-person GP managing your GLP-1 monitoring delivers the full clinical picture — blood tests, liver assessment, dietitian referral, and specialist referral if needed. The Chronic Disease Management Plan from your GP provides Medicare-subsidised access to dietitian consultations (up to 5 per year).
The optimal model: Many patients use telehealth for the prescription and convenience, while establishing a separate relationship with an in-person GP specifically for monitoring blood tests, FIB-4 calculation, elastography referral, and dietitian coordination. This hybrid approach captures the accessibility of telehealth with the clinical depth of GP monitoring.
How to find a GP for GLP-1 monitoring in Australia →
What monitoring you need on GLP-1 medications →
Ozempic and Off-Label Prescribing — Important Update
From October 2024, new off-label private prescriptions for Ozempic (semaglutide) specifically for weight loss in non-diabetic patients were heavily restricted in Australia. Existing patients on off-label scripts can continue. For weight management without type 2 diabetes, Wegovy (semaglutide 2.4mg) is the TGA-approved product. Both telehealth and in-person doctors are subject to this restriction.
Pharmacies can no longer compound replicas of GLP-1 drugs in Australia. Compounded semaglutide or tirzepatide is not legally available from Australian compounding pharmacies as of October 2024.
Find a liver elastography clinic near you
Search by suburb or postcode to see accredited clinics offering FibroScan and guided liver elastography across Australia.
Type a suburb or postcode and press Enter to search nearby.
Request a liver scan appointment
Submit your details and we'll route your request to the most appropriate elastography clinic in your area. Most clinics respond within 1–2 business days.
Take action
Request an appointment
Frequently asked questions
Is it safe to get a GLP-1 prescription through telehealth in Australia?
Yes — Australian telehealth GLP-1 prescriptions are issued by AHPRA-registered doctors following the same legal and clinical standards as in-person prescriptions. The safety of the prescribing process is comparable. The difference is in the comprehensiveness of monitoring after the prescription is issued.
What does a telehealth GLP-1 consultation miss?
Primarily: physical examination (blood pressure measurement, abdominal assessment), baseline blood tests (liver function, kidney function, thyroid, FIB-4 calculation), liver elastography referral if FIB-4 is indeterminate, and dietitian referral via Chronic Disease Management Plan. These are the elements of the monitoring pathway recommended by the MJA September 2025 consensus statement.
Can I get the CDM Plan through a telehealth GP?
Yes — a telehealth GP can create a Chronic Disease Management Plan and refer you to a dietitian with Medicare rebates, just as an in-person GP can. The plan provides up to 5 allied health consultations per year. Ask specifically whether your telehealth provider offers CDM Plan creation.
Do I need to tell my telehealth provider about monitoring I'm getting elsewhere?
Yes. If you are getting blood tests and monitoring from a separate in-person GP, share those results with your telehealth prescriber. Both providers need to know what the other is managing.
Is in-person GLP-1 care covered by Medicare in Australia?
GP consultations for GLP-1 monitoring are bulk-billed or attract a Medicare rebate depending on your GP's billing model. Blood tests ordered during those consultations are generally bulk-billed under an appropriate clinical indication. Liver elastography does not currently attract a Medicare rebate for most MASLD indications.
Sources: Journal of Medical Internet Research — After the Prescription telehealth GLP-1 care 2026 (DOI: 10.2196/101874); Obesity Reviews scoping review 2026; weightloss.com.au weight loss medication Australia 2026; Regimen Ozempic Mounjaro PBS guide April 2026; MJA MAFLD consensus statement September 2025 (DOI: 10.5694/mja2.70008).
This article is for educational purposes only. It does not constitute medical advice. Always consult your GP or a specialist about your individual health circumstances.
Next step
Find a liver elastography clinic near you
Search participating clinics across Australia, or talk to your GP about a baseline FIB-4 and elastography.